Omnicell, Inc. (NASDAQ:OMCL) Shares Sold by Quest Partners LLC

Quest Partners LLC decreased its position in shares of Omnicell, Inc. (NASDAQ:OMCL) by 16.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,094 shares of the company’s stock after selling 591 shares during the quarter. Quest Partners LLC’s holdings in Omnicell were worth $84,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in OMCL. Charles Schwab Investment Management Inc. increased its holdings in Omnicell by 7.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 483,443 shares of the company’s stock valued at $18,192,000 after buying an additional 32,548 shares in the last quarter. Dimensional Fund Advisors LP grew its position in shares of Omnicell by 2.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,067,516 shares of the company’s stock valued at $40,173,000 after acquiring an additional 21,798 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of Omnicell by 106.1% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 16,428 shares of the company’s stock valued at $618,000 after purchasing an additional 8,457 shares in the last quarter. Panagora Asset Management Inc. acquired a new position in Omnicell in the 4th quarter worth about $1,319,000. Finally, Norges Bank purchased a new position in Omnicell during the fourth quarter worth approximately $18,802,000. 97.70% of the stock is owned by hedge funds and other institutional investors.

Omnicell Stock Performance

NASDAQ:OMCL opened at $44.92 on Wednesday. The company has a market cap of $2.07 billion, a P/E ratio of -97.65, a P/E/G ratio of 47.22 and a beta of 0.83. Omnicell, Inc. has a twelve month low of $25.12 and a twelve month high of $56.05. The company’s 50-day moving average price is $38.17 and its 200-day moving average price is $31.96. The company has a current ratio of 2.45, a quick ratio of 2.22 and a debt-to-equity ratio of 0.47.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Thursday, August 1st. The company reported $0.51 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.37. The company had revenue of $276.80 million during the quarter, compared to the consensus estimate of $254.41 million. Omnicell had a negative net margin of 1.92% and a positive return on equity of 2.52%. Omnicell’s quarterly revenue was down 7.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.29 EPS. On average, sell-side analysts forecast that Omnicell, Inc. will post 0.64 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. StockNews.com raised Omnicell from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Bank of America upped their price objective on shares of Omnicell from $34.00 to $44.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Benchmark reiterated a “buy” rating and issued a $38.00 target price on shares of Omnicell in a research report on Monday, July 15th. Wells Fargo & Company upped their price target on shares of Omnicell from $26.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Friday, August 2nd. Finally, Barclays upgraded Omnicell from an “underweight” rating to an “equal weight” rating and lifted their price objective for the stock from $26.00 to $39.00 in a report on Friday, August 2nd. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $37.83.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.